Physician profile
Mimi Oliff
NPI 1568772093
$9,771.34
in general payments reported to CMS, 2019-2025
28 companies · $2,834 in 2025
The $2,834 reported for 2025 was more than what 98% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,123 · 2022: $1,311 · 2023: $1,683 · 2024: $2,820 · 2025: $2,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,043 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,043.01 |
| Education | $294.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,439.89 | 2021-2025 | |
| Janssen Biotech, INC. | $1,320.62 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Galderma Laboratories, L.P. | $897.32 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Regeneron Healthcare Solutions, INC. | $775.07 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $625.97 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $557.75 | 2023-2025 | Zoryve |
| Pfizer INC. | $555.81 | 2021-2025 | |
| Leo Pharma INC. | $465.17 | 2021-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $414.40 | 2021-2025 | Blu-U, Odomzo, Absorica Ld |
| Incyte Corporation | $402.88 | 2021-2025 | Opzelura |
| Genzyme Corporation | $383.74 | 2021-2025 | |
| Amgen INC. | $341.60 | 2022-2025 | Otezla, Otezla |
| Journey Medical Corporation | $286.05 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $235.10 | 2021-2025 | Jublia, Arazlo, Duobrii |
| Novartis Pharmaceuticals Corporation | $199.28 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $169.97 | 2021-2025 | |
| Ucb, INC. | $169.08 | 2022-2025 | Bimzelx |
| Botanix Sb INC | $110.30 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $104.64 | 2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $74.09 | 2021 | |
| Epi Health, LLC | $54.79 | 2021-2022 | |
| Revance Therapeutics, INC. | $53.02 | 2024 | Daxxify |
| Almirall LLC | $43.47 | 2023-2025 | Seysara, Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.67 | 2022-2023 | Spevigo |
| Biofrontera INC. | $17.94 | 2025 | |
| Genentech USA, INC. | $15.36 | 2023 | Erivedge |
| Lnhc, INC | $14.75 | 2025 | Zelsuvmi |
| Convatec INC. | $13.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Oliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.